XELOX followed by XELIRI or the reverse sequence in advanced colorectal cancer

Oncology

Volumn 73, Issue 5-6, 2008, Pages 298-304

  Sakar, B ^a   Gumus, M ^b   Basaran, M ^a   Argon, A ^c   Ustuner, Z ^d   Ustaoglu, M A ^e   Saglam, S ^a   Guney, N ^a   Tenekeci, A N ^a   Aykan, N F ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b Kartal Lutfi Kirdar Education and Research Hospital   (Turkey)

^c SISLI ETFAL TRAINING AND RESEARCH HOSPITAL   (Turkey)

^d Osman Gazi Medical Faculty   (Turkey)

^e GATA HAYDARPASA TRAINING HOSPITAL   (Turkey)

Author keywords

Advanced disease; Capecitabine; Colorectal cancer; Combination chemotherapy

Indexed keywords

ALKALINE PHOSPHATASE; CAPECITABINE; DEXAMETHASONE; IRINOTECAN; LACTATE DEHYDROGENASE; OXALIPLATIN; SEROTONIN 3 ANTAGONIST;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CANCER SURVIVAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HUMAN; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NAUSEA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; PROGNOSIS; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; L-LACTATE DEHYDROGENASE; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PILOT PROJECTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 45549100405     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000132395     Document Type: Article

References (14)

1. Miwa M, Ura M, Nishida M, et al: Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998;34:1274-1281.
2. Van Cutsem E, Hoff P, Harper P, et al: Oral capecitabine versus intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. Br J Cancer 2004;90:1190-1197.
3. Cassidy J, Twelves C, Van Cutsem E, et al: First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol 2004;13:566-575.
4. Díaz-Rubio E, Evans TR, Tabernero J, et al: Capecitabine (Xeloda) in combination with oxaliplatin: a phase I, dose-escalation study in patients with advanced or metastatic solid tumors. Ann Oncol 2002;13:558-565.
5. Schmoll HJ, Grothey A, Kroening H, et al: A phase II study comparing bolus 5- fluorouracil/folinic acid (Mayo Clinic) with weekly 24 h infusion of high-dose 5-fluorouracil/folinic acid plus oxaliplatin as first-line therapy in advanced colorectal cancer, submitted.
6. Cassidy J, Tabernero J, Twelves C, et al: XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 2004;22:2084-2091.
7. Goldberg RM, Sargent DJ, Morton RF, et al: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22:23-30.
8. Bajetta E, Di Bartolomeo M, Mariani L, et al: Randomized multicenter phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma. Cancer 2004;100:279-287.
9. Tournigand C, Andre T, Achille E, et al: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004;22:229-237.
10. Cassidy J, Clarke S, Diaz-Rubio E, et al: XELOX vs. FOLFOX4: efficacy results from XELOX-1/N016966, a randomized phase III trial in first-line metastatic colorectal cancer (MCRC) (abstract). Data presented at the 4th Annual ASCO Gastrointestinal Cancers Symposium, Orlando, January 20, 2007.
11. Hochster HS, Hart LL, Ramanathan RK, et al: Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC): Final analysis of the TREE study (abstract). J Clin Oncol 2006;24:148s.
12. Borner MM, Bernhard J, Dietrich D, et al: A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity. Ann Oncol 2005;16:282-288.
13. Goldberg RM, Sargent DJ, Morton RF, et al: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22:23-30.
14. Blum JL, Jones SE, Buzdar AU, et al: Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1999;17:485-493.